Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses
The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.
You may also be interested in...
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
Regeneron hopes to bolster its immuno-oncology pipeline with the acquisition of Checkmate, which joins a spate of similar deals suggesting renewed interest in biotech investment despite an industry-wide slowdown.